EA202090814A1 - Способы и композиции для лечения буллезного эпидермолиза - Google Patents

Способы и композиции для лечения буллезного эпидермолиза

Info

Publication number
EA202090814A1
EA202090814A1 EA202090814A EA202090814A EA202090814A1 EA 202090814 A1 EA202090814 A1 EA 202090814A1 EA 202090814 A EA202090814 A EA 202090814A EA 202090814 A EA202090814 A EA 202090814A EA 202090814 A1 EA202090814 A1 EA 202090814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
ballous
epidermolysis
treatment
Prior art date
Application number
EA202090814A
Other languages
English (en)
Inventor
Евангелос В. Бадиавас
Original Assignee
Юниверсити Оф Майами
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US20180104186A1/en
Application filed by Юниверсити Оф Майами filed Critical Юниверсити Оф Майами
Publication of EA202090814A1 publication Critical patent/EA202090814A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены композиции и способы для лечения буллезного эпидермолиза.
EA202090814A 2017-09-22 2018-09-21 Способы и композиции для лечения буллезного эпидермолиза EA202090814A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US20180104186A1 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (en) 2017-09-22 2018-09-21 METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS

Publications (1)

Publication Number Publication Date
EA202090814A1 true EA202090814A1 (ru) 2020-08-07

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090814A EA202090814A1 (ru) 2017-09-22 2018-09-21 Способы и композиции для лечения буллезного эпидермолиза

Country Status (10)

Country Link
EP (1) EP3684336A4 (ru)
JP (1) JP2020534344A (ru)
KR (1) KR20200088799A (ru)
CN (1) CN111182890A (ru)
AU (1) AU2018335788A1 (ru)
CA (1) CA3076610A1 (ru)
EA (1) EA202090814A1 (ru)
IL (1) IL273407A (ru)
MX (2) MX2020002777A (ru)
WO (1) WO2019060719A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
KR102125567B1 (ko) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
KR20230043906A (ko) * 2020-07-22 2023-03-31 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 영양 장애형 표피 수포증의 치료약
KR20230074475A (ko) * 2020-08-21 2023-05-30 더 유니버시티 오브 마이애미 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법
EP3971440B1 (en) 2020-09-21 2023-12-27 Brembo S.p.A. Braking band of a disc brake disc and disc brake disc
GB202402730D0 (en) * 2021-08-12 2024-04-10 Onconova Therapeutics Inc Methods and compositions for treating cancer
AU2022363859A1 (en) * 2021-10-12 2024-05-02 Eliksa Therapeutics, Inc. Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2778098T3 (es) * 2013-03-13 2020-08-07 Univ Miami Método de aislamiento y purificación de microvesículas de sobrenadantes de cultivo celular y fluidos biológicos
US20160220613A1 (en) * 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
KR20170085010A (ko) * 2016-01-12 2017-07-21 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
EP3922253A1 (en) * 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use

Also Published As

Publication number Publication date
KR20200088799A (ko) 2020-07-23
EP3684336A4 (en) 2021-06-02
CA3076610A1 (en) 2019-03-28
MX2020002777A (es) 2020-09-17
AU2018335788A1 (en) 2020-03-19
WO2019060719A1 (en) 2019-03-28
IL273407A (en) 2020-05-31
JP2020534344A (ja) 2020-11-26
EP3684336A1 (en) 2020-07-29
CN111182890A (zh) 2020-05-19
MX2022015753A (es) 2023-01-19

Similar Documents

Publication Publication Date Title
EA202090814A1 (ru) Способы и композиции для лечения буллезного эпидермолиза
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123196T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
SG11202010830WA (en) Methods of treating phenylketonuria
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EA201691896A1 (ru) Соединения и способы их применения
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения